Contact this trialFirst, we need to learn more about you.
Dopamine Agonist
CTC-413 for Parkinson's Disease
Recruiting1 awardPhase 2
Farmington Hills, Michigan
This trial tests a combination of Pramipexole ER and Aprepitant in patients with idiopathic Parkinson's disease. Pramipexole ER helps reduce Parkinson's symptoms by mimicking dopamine, while Aprepitant prevents nausea to improve tolerance of the treatment. Pramipexole is used to treat Parkinson's disease and is effective in both early and advanced stages.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service